<DOC>
	<DOCNO>NCT00821574</DOCNO>
	<brief_summary>This study evaluate efficacy multi factorial preventive scheme action ( include fluvastatin valsartan ) reduce overall risk level patient metabolic syndrome .</brief_summary>
	<brief_title>Reducing Overall Risk Level Patients Suffering From Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Fluvastatin</mesh_term>
	<criteria>Age 40 65 year Diagnosed metabolic syndrome Risk cardiovascular death â‰¥ 5 % ( accord SCORE ) Written informed consent Women menopause use efficient contraception Known hypersensitivity study drug History ischemic heart disease</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hypertension , dyslipidemia</keyword>
</DOC>